Cargando…

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia

Paliperidone, the major active metabolite of risperidone, is a second-generation antipsychotic that has been developed as an extended-release (ER) tablet formulation that minimizes peak-trough fluctuations in plasma concentrations, allowing once-daily administration and constant drug delivery. Palip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spina, Edoardo, Crupi, Rosalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663611/ https://www.ncbi.nlm.nih.gov/pubmed/23861636 http://dx.doi.org/10.4137/JCNSD.S1607

Ejemplares similares

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
por: Kim, Shiyun, et al.
Publicado: (2012)

Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia
por: Helldin, Lars, et al.
Publicado: (2015)

Effects of paliperidone extended release on the symptoms and functioning of schizophrenia
por: Huang, Min-Wei, et al.
Publicado: (2012)

Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
por: Levitan, Bennett, et al.
Publicado: (2016)

Role of paliperidone extended-release in treatment of schizoaffective disorder
por: Canuso, Carla M, et al.
Publicado: (2010)

The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino, Jehan, et al.
Publicado: (2012)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
por: Jariyavilas, Apichat, et al.
Publicado: (2017)

Treatment of bipolar mania with paliperidone extended-release
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)
por: Jung, Seung-Ho, et al.
Publicado: (2013)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2008)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso, Claudio, et al.
Publicado: (2017)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
por: Nakagawa, Ryoko, et al.
Publicado: (2015)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
por: Chen, Ching-Yen, et al.
Publicado: (2018)

Paliperidone extended-release: does it have a place in antipsychotic therapy?
por: Gahr, Maximilian, et al.
Publicado: (2011)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
por: Cai, Shangli, et al.
Publicado: (2015)

Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder
por: Yamamuro, Kazuhiko, et al.
Publicado: (2014)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang, Fan, et al.
Publicado: (2015)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
por: Emsley, Robin, et al.
Publicado: (2018)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang, Fu De, et al.
Publicado: (2017)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang, Hongyan, et al.
Publicado: (2016)

PM380. Treatment successful rate and efficacy of Paliperidone ER in patients with acute schizophrenia
por: Chen, Yi-hsing
Publicado: (2016)

Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate
por: Pai, Nagesh, et al.
Publicado: (2018)

Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study
por: Si, Tian Mei, et al.
Publicado: (2019)

Evaluation of sleep profile in schizophrenia patients treated with extended-release paliperidone: an open-label prospective study in Southeast Asia
por: Kongsakon, Ronnachai, et al.
Publicado: (2017)

Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study()
por: Pandina, Gahan, et al.
Publicado: (2020)

Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial
por: Kang, Nam-In, et al.
Publicado: (2016)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Bishara, Delia
Publicado: (2010)

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
por: Druais, Sylvain, et al.
Publicado: (2016)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
por: Carpiniello, Bernardo, et al.
Publicado: (2016)

Paliperidone: the evidence of its therapeutic value in schizophrenia
por: Kantrowitz, Joshua, et al.
Publicado: (2007)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
por: Shi, Chuan, et al.
Publicado: (2016)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study
por: Geitona, Maria, et al.
Publicado: (2008)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study
por: Geitona, Maria, et al.
Publicado: (2009)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si, Tianmei, et al.
Publicado: (2019)

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
por: Ulahannan, Danny, et al.
Publicado: (2009)

Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients
por: Błaszczyk, Barbara, et al.
Publicado: (2010)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
por: Zhang, LiLi, et al.
Publicado: (2016)

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
por: Si, Tianmei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_36984m3tq292761hg8bhfjsjsa